Chronic inflammation, which is caused by infectious agents or exposure to environmental factors such as heterocyclic amines, is believed to play a role in up 20% of adult cancers. In prostate, genetic, molecular pathology, and toxicology data suggest that inflammation-related processes are involved in cancer development, but these data conflict with results of epidemiological studies that show an inverse correlation between inflammation and prostate cancer risk. This may be due to bias in the factors that lead men to undergo prostate biopsy, as well as complexity of the inflammatory phenotype itself. Our proposed study will address this paradox by dissecting inflammation at the cellular, molecular, and clinical level. The Henry Ford Health System biorepository contains benign prostate tissue specimens collected from over 9,000 men over the past 20 years, including over 1,000 men who subsequently developed prostate cancer. Using this unique cohort with its annotated clinical baseline and follow-up data, we will conduct a nested case-control study of 700 prostate cancer case-control pairs. Characterizing inflammatory markers in these pre-disease specimens will allow us to determine the nature of tumor-suppressive vs. tumor-supportive inflammatory signatures. We will also measure telomere length in the same benign prostate tissue specimens in which we characterize inflammation to assign a malignancy-potential signature to each specimen. Approximately 1 million prostate biopsies are performed annually in the US, twothirds of which reveal benign condition. Our cohort includes a large group of patients who are at high risk of prostate cancer despite a negative biopsy. An in-depth characterization of inflammation in the benign prostate, before histologic signs of malignancy become apparent, will provide insight into the type of inflammatory milieu associated with eventual tumor development as well as cancer progression and recurrence. A better understanding of the clinical implications of chronic inflammation of the prostate so often observed in older men can have significant impact upon millions of men where currently a negative biopsy offers little reassurance in terms of prostate cancer outcomes.

Public Health Relevance

Approximately 1 million prostate biopsies are performed annually in the US, two-thirds of which reveal benign conditions, but often with histologic inflammation. The proposed study seeks to clarify the role of histologic inflammation in the development of prostate cancer thereby providing targets for prevention and treatment.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
2R01ES011126-11A1
Application #
8761443
Study Section
Epidemiology of Cancer Study Section (EPIC)
Program Officer
Mcallister, Kimberly A
Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Henry Ford Health System
Department
Type
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Rybicki, Benjamin A; Rundle, Andrew; Kryvenko, Oleksandr N et al. (2016) Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer. Int J Cancer 138:2884-93
Rybicki, B A; Kryvenko, O N; Wang, Y et al. (2016) Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer. Prostate Cancer Prostatic Dis 19:145-50
Rand, Kristin A; Rohland, Nadin; Tandon, Arti et al. (2016) Whole-exome sequencing of over 4100 men of African ancestry and prostate cancer risk. Hum Mol Genet 25:371-81
Han, Ying; Signorello, Lisa B; Strom, Sara S et al. (2015) Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer 136:1210-7
Han, Ying; Hazelett, Dennis J; Wiklund, Fredrik et al. (2015) Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Hum Mol Genet 24:5603-18
Barber, Alison G; Castillo-Martin, Mireia; Bonal, Dennis M et al. (2015) PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer. Cancer Med 4:1258-71
Kataria, Yachana; Wright, Margaret; Deaton, Ryan J et al. (2015) Dietary influences on tissue concentrations of phytanic acid and AMACR expression in the benign human prostate. Prostate 75:200-10
Zaitlen, Noah; Pasaniuc, Bogdan; Sankararaman, Sriram et al. (2014) Leveraging population admixture to characterize the heritability of complex traits. Nat Genet 46:1356-62
Barber, Alison G; Castillo-Martin, Mireia; Bonal, Dennis M et al. (2014) Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer. PLoS One 9:e98786
Al Olama, Ali Amin; Kote-Jarai, Zsofia; Berndt, Sonja I et al. (2014) A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 46:1103-9

Showing the most recent 10 out of 48 publications